Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Liumei X"'
Autor:
Tianze Li, Liqin Sun, Yun He, Yang Zhou, Liumei Xu, Fang Zhao, Dongsheng Hu, Hui Wang, Hongzhou Lu, Jiaye Liu
Publikováno v:
Frontiers in Public Health, Vol 11 (2023)
BackgroundWith the early initiation of antiretroviral therapy (ART) in China, the demographics of treatment-naïve people living with HIV (PLWH) are moving closer to those of the general population, which is characterized by a gradual increase in met
Externí odkaz:
https://doaj.org/article/d67bea148a8c4bdeb0e13d92da7f3579
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 18, Iss 6 (2022)
In the global context of the COVID-19 pandemic, the overall benefits of getting any COVID-19 vaccine approved by the World Health Organization for emergency use outweigh the potential risks, even in people with weakened immune systems, including peop
Externí odkaz:
https://doaj.org/article/833543f4a14b4d35a07c8d7bec9cb74b
Autor:
Jiaye Liu, Yuying Hou, Liqin Sun, Lifeng Wang, Yun He, Yang Zhou, Liumei Xu, Xiaoning Liu, Fang Zhao, Lukun Zhang, Hui Wang, Fu-Sheng Wang
Publikováno v:
Emerging Microbes and Infections, Vol 10, Iss 1, Pp 416-423 (2021)
Morbidity and mortality of non-AIDS-defining diseases (NADs) have become the increasing burden of people living with HIV (PLWH) with long-term antiretroviral therapy (ART). We aimed to quantify the contribution of modifiable risk factors to NADs. We
Externí odkaz:
https://doaj.org/article/451f695319a74eaaadd43c72116361ef
Autor:
Guang Zeng, Liumei Xu, Shuidong Feng, Jie Tang, Xiaohui Wang, Guilian Li, Yongxia Gan, Chenli Zheng, Jin Zhao, Zhengrong Yang
Publikováno v:
Vaccines, Vol 10, Iss 6, p 880 (2022)
The purpose of this study was to preliminarily evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in PLWH in the real world. We collected blood samples from 132 PLWH aged 18–59 years who were vaccinated with two d
Externí odkaz:
https://doaj.org/article/454a91b6987d4b9f868542f67a400c5c
Autor:
Xiaojie Huang, Liumei Xu, Lijun Sun, Guiju Gao, Weiping Cai, Yanfen Liu, Haibo Ding, Hongxia Wei, Ping Ma, Min Wang, Shuiqing Liu, Yaokai Chen, Xiaohong Chen, Qingxia Zhao, Jianhua Yu, Yuxia Song, Hui Chen, Hao Wu, Shanfang Qin, Linghua Li
Publikováno v:
Frontiers in Pharmacology, Vol 10 (2019)
The World Health Organization guidelines recommend lopinavir/ritonavir (LPV/r) as a second-line antiretroviral therapy (ART) for HIV-infected adults in middle-income and low-income countries as a protease inhibitor boost based on clinical trials; how
Externí odkaz:
https://doaj.org/article/c20ededb4bdf4553a0e4259d837de9e5
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.